Ardelyx shares rose 8.6% after earnings, with investors responding to Q3 revenue growth of 19% year over year and progress on pipeline expansion. IBSRELA’s 23% growth led the quarter, while XPHOZAH grew 7%, a more modest pace.
Ardelyx shares fell 18.5% after the company cut guidance in response to growing payer hurdles that slowed new patient starts for IBSRELA, signaling investor concerns over demand deceleration despite revenue growth.
Ardelyx demonstrated strong performance in Q3 2025, driven by robust growth in product revenues, particularly from IBSRELA, which saw a 92% year-over-year increase.